Free

A fourth board for former FDA Commissioner

Here at Footnoted.com, we hope that everybody enjoyed their Thanksgiving, whether that meant a big meal with extended family, a cozy dinner for two or takeout. Our best guess is Dr. Scott Gottlieb probably did.

Late on November 21, UnitedHealth Group, which has had a very rocky year following the murder of Brian Thompson, the CEO of its largest subsidiary, last Dec. 4, filed this 8-K where it named Gottlieb, the former Food and Drug Administration commissioner from 2017 to 2019, to its board of directors.

To be clear, Gottlieb is no boardroom rookie. He currently serves as a director at three other publicly traded medical-related companies—drug giant Pfizer, genetics company Illumina, and Tempus AI, a medical diagnostics and research company.

That’s a lot of corporate boards at a time when many companies are heading in the opposite direction and limiting the number of boards directors can sit on.  Gottlieb is also a partner at prominent venture capital firm New Enterprise Associates and a senior fellow at the American Enterprise Institute, the Washington, DC think tank, among other activities. In other words: he’s a busy fellow.

Once upon a time, it was more common for a director to sit on multiple boards. That’s even more so for big-name directors, like Gottlieb. Nearly two decades ago, UnitedHealth used to let its directors sit on six different boards, according to prior proxy statements. But it changed the rule around 15 years ago, limiting its directors to three additional boards.

Statistics show that only 6% of all directors in the S&P 500 sit on four boards, so Gottlieb is clearly an outlier here. Still, as the role of a director has grown more complex, many companies have put limits on the number of boards a director can serve on.

A quick skim of the proxy statements for those four companies shows that Gottlieb stands to make about $1.5 million a year as a board member at those four different companies. According to their latest proxies Pfizer coughed up a total of $390,000 in 2024 for Gottlieb; Tempus AI,  $556,268; and Illumina, $404,056. UNH adds another $350K to that total. And, as much as being a director has gotten more complicated, it remains a part-time job.

Given what’s going on in healthcare, including some of the attacks that President Trump has made on the for-profit health insurance companies, it certainly makes sense to have a former government official like Gottlieb, with ties to the Trump Administration, as a director. Think of it as an insurance policy for an insurance provider.